Italian Genenta Science’s Original Strategy to Treat Cancer

27/01/2015 - 2 minutes

Tumor microenvironment, including tumor-associated macrophages, plays a key role in controlling tumor progression and response to therapies. It stimulates tumor growth, supports angiogenesis and tissue remodeling, as well as neutralizes host immunity. Genenta Science is using this mechanism, which is certainly a promising area of cancer biology for the identification of new therapeutic targets.

In less than five months since its foundation, Genenta Science raised €6.2M. The funding campaign was backed by Banca Esperia, the private bank of Mediobanca, and Mediolanum. The entrance of new shareholders allows Genenta Science to complete the pre-clinical studies and to advance in the preparation of the clinical phase for its therapeutic protocols to treat tumors.
Genenta Science technology involves the use of interferons; proteins that are usually produced by the body in response to infections that also exhibit a powerful anti-tumor activity. However, the clinical use of interferon as a drug has been limited due to its high toxicity.
Genenta Science’s innovative therapy uses a combination of transcriptional and microRNA‐mediated control, so tumor-infiltrating monocytes/macrophages become capable of selectively expressing interferon limited to the tumor area,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member